Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229–263 (2024).

Article  PubMed  Google Scholar 

Liu, K. et al. Changes of esophagogastric junctional adenocarcinoma and gastroesophageal reflux disease among surgical patients during 1988-2012: a single-institution, high-volume experience in China. Ann. Surg. 263, 88–95 (2016).

Article  PubMed  Google Scholar 

Arnold, M., Ferlay, J., van Berge Henegouwen, M. I. & Soerjomataram, I. Global burden of oesophageal and gastric cancer by histology and subsite in 2018. Gut 69, 1564–1571 (2020).

Article  PubMed  Google Scholar 

Sano, T. et al. Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project. Gastric Cancer 20, 217–225 (2017).

Article  PubMed  Google Scholar 

Nie, R. C. et al. Adjuvant chemotherapy for patients with adenocarcinoma of the esophagogastric junction: a retrospective, multicenter, observational study. Ann. Surg. Oncol. 30, 4014–4025 (2023).

Article  PubMed  Google Scholar 

Gavin, A. T. et al. Oesophageal cancer survival in Europe: a EUROCARE-4 study. Cancer Epidemiol. 36, 505–512 (2012).

Article  CAS  PubMed  Google Scholar 

Suh, Y. S. et al. Comprehensive molecular characterization of adenocarcinoma of the gastroesophageal junction between esophageal and gastric adenocarcinomas. Ann. Surg. 275, 706–717 (2022).

Article  PubMed  Google Scholar 

Ajani, J. A. et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc Netw. 20, 167–192 (2022).

Article  CAS  PubMed  Google Scholar 

Ajani, J. A. et al. Esophageal and esophagogastric junction cancers, Version 2.2023, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc Netw. 21, 393–422 (2023).

Article  PubMed  Google Scholar 

Wang, F. H. et al. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Commun. (Lond.) 44, 127–172 (2024).

Article  CAS  PubMed  Google Scholar 

Lordick, F. et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 1005–1020 (2022).

Article  CAS  PubMed  Google Scholar 

van Hagen, P. et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N. Engl. J. Med. 366, 2074–2084 (2012).

Article  PubMed  Google Scholar 

Faron, M. et al. Individual participant data network meta-analysis of neoadjuvant chemotherapy or chemoradiotherapy in esophageal or gastroesophageal junction carcinoma. J. Clin. Oncol. 41, 4535–4547 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al-Batran, S. E. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 393, 1948–1957 (2019).

Article  PubMed  Google Scholar 

Zhang, X. et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 22, 1081–1092 (2021).

Article  CAS  PubMed  Google Scholar 

Japanese Gastric Cancer, A. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer, 1-25 (2023).

Guideline Committee of the Korean Gastric Cancer Association, D. W. G. & Review, P. Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach. J Gastric Cancer 19, 1–48 (2019).

Sasako, M. et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J. Clin. Oncol. 29, 4387–4393 (2011).

Article  CAS  PubMed  Google Scholar 

Noh, S. H. et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 15, 1389–1396 (2014).

Article  CAS  PubMed  Google Scholar 

Leong, T. et al. Preoperative chemoradiotherapy for resectable gastric cancer. N. Engl. J. Med. 391, 1810–1821 (2024).

Article  CAS  PubMed  Google Scholar 

Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398, 27–40 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kang, Y. K. et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 23, 234–247 (2022).

Article  CAS  PubMed  Google Scholar 

Rha, S. Y. et al. Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study. Ann. Oncol. 34, 319–320 (2023).

Article  Google Scholar 

Moehler, M. H. et al. Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). J. Clin. Oncol. 41, 286–286 (2023).

Article  Google Scholar 

Rha, S. Y. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 24, 1181–1195 (2023).

Article  CAS  PubMed  Google Scholar 

Xu, J. et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. JAMA 330, 2064–2074 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Lorenzen, S. et al. Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II/III DANTE/IKF-s633 Trial. J. Clin. Oncol. 42, 410–420 (2024).

Article  CAS  PubMed  Google Scholar 

Yin, Y. et al. Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial. Front Oncol. 12, 959295 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yuan, S. Q. et al. Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial. Nat. Med 30, 552–559 (2024).

Article  CAS  PubMed  Google Scholar 

Shitara, K. et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 25, 212–224 (2024).

Article  CAS  PubMed  Google Scholar 

Janjigian, Y. Y. et al. Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study. Ann. Oncol. 34, S1315–S1316 (2023).

Article  Google Scholar 

André, T. et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. J. Clin. Oncol. 41, 255–265 (2023).

Article  PubMed  Google Scholar 

Doroshow, D. B. et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 18, 345–362 (2021).

Article  CAS  PubMed  Google Scholar 

Wang, Y. et al. Challenges coexist with opportunities: spatial heterogeneity expression of PD-L1 in cancer therapy. Adv. Sci. (Weinh.) 11, e2303175 (2024).

PubMed